Valuation: Xenon Pharmaceuticals Inc.

Market Cap 3.49B 3.13B 2.89B 2.62B 4.89B 332B 4.95B 34.59B 13.78B 174B 13.09B 12.81B 552B P/E 2026 *
-7.76x
P/E 2027 * -7.71x
Enterprise Value 2.44B 2.19B 2.02B 1.83B 3.43B 232B 3.47B 24.21B 9.64B 122B 9.16B 8.97B 386B EV / Sales 2026 *
1,942x
EV / Sales 2027 * 100x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Xenon Pharmaceuticals Inc.

1 day+0.60%
1 week+0.56%
Current month-2.80%
1 month-1.55%
3 months-44.33%
6 months-33.71%
Current year-19.34%
1 week 35.09
Extreme 35.09
36.9
1 month 33.38
Extreme 33.38
39.92
Current year 33.38
Extreme 33.38
72.66
1 year 33.38
Extreme 33.38
72.66
3 years 26.74
Extreme 26.74
72.66
5 years 23.26
Extreme 23.26
72.66
10 years 2.1
Extreme 2.1
72.66
Manager TitleAgeSince
Chief Executive Officer 50 2021-06-02
Director of Finance/CFO 55 2025-10-14
Chief Operating Officer 54 2024-08-11
Director TitleAgeSince
Director/Board Member 67 2003-12-31
Director/Board Member 50 2021-06-02
Director/Board Member 64 2015-05-20
Date Insider Type Main position Quantity % Market Cap. Importance
10/15/26 Exercice

Chief Financial Officer

15,000 0.0155%
9/30/26 Buy

Chief Executive Officer

30,000 0.0310%
9/30/26 Buy

Chief Financial Officer

15,000 0.0155%
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%+0.56%-15.00%+14.76% 3.49B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.10%-0.08%+26.71%+56.02% 44.75B
+1.86%-3.48%+17.72%+99.88% 41.62B
+0.43%-3.82%+221.21%+918.26% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.98%-0.45%+44.95%+147.06% 38.39B
Weighted average by Cap. +3.01%-0.29%+46.50%+159.12%

Financials

2026 *2027 *
Net sales 1.26M 1.13M 1.04M 944K 1.76M 120M 1.79M 12.47M 4.97M 62.65M 4.72M 4.62M 199M 26.97M 24.2M 22.37M 20.26M 37.86M 2.57B 38.32M 268M 107M 1.34B 101M 99.09M 4.27B
Net income -447M -401M -371M -336M -628M -42.59B -635M -4.43B -1.77B -22.28B -1.68B -1.64B -70.75B -486M -436M -403M -365M -682M -46.25B -690M -4.82B -1.92B -24.2B -1.82B -1.78B -76.84B
Net Debt -1.05B -939M -868M -786M -1.47B -99.65B -1.49B -10.38B -4.13B -52.15B -3.93B -3.84B -166B -789M -708M -654M -593M -1.11B -75.12B -1.12B -7.82B -3.12B -39.31B -2.96B -2.9B -125B
Projected Income Statement - Annual - Xenon Pharmaceuticals Inc.
Logo Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Employees
364
Date Price Change Volume
26-10-28 US$36.16 +0.40% 1,469,648
26-10-27 US$36.01 +0.67% 1,089,964
26-10-26 US$35.77 +1.22% 726,713
26-10-23 US$35.34 -3.18% 636,595
26-10-22 US$36.50 +1.53% 1,375,539
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Xenon Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
36.01USD
Average target price
71.94USD
Spread / Average Target
+99.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Xenon Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. XENE Stock